CN102712628B - 丙型肝炎病毒抑制剂 - Google Patents
丙型肝炎病毒抑制剂 Download PDFInfo
- Publication number
- CN102712628B CN102712628B CN201080061374.4A CN201080061374A CN102712628B CN 102712628 B CN102712628 B CN 102712628B CN 201080061374 A CN201080061374 A CN 201080061374A CN 102712628 B CN102712628 B CN 102712628B
- Authority
- CN
- China
- Prior art keywords
- pyrrolidyl
- imidazol
- solvent
- bis
- imidazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C#Cc1ccccc1 Chemical compound *C#Cc1ccccc1 0.000 description 9
- CBESSEJGYHLVPG-UHFFFAOYSA-N Brc1cnc(-c([s]2)ncc2Br)[s]1 Chemical compound Brc1cnc(-c([s]2)ncc2Br)[s]1 CBESSEJGYHLVPG-UHFFFAOYSA-N 0.000 description 1
- MGGKZKSIKOPMQS-RJAALHMKSA-N C(C1)CN[C@@H]1c1nc(/C=C/c2ccc(/C=C/c3cnc(C4NCCC4)[nH]3)cc2)c[nH]1 Chemical compound C(C1)CN[C@@H]1c1nc(/C=C/c2ccc(/C=C/c3cnc(C4NCCC4)[nH]3)cc2)c[nH]1 MGGKZKSIKOPMQS-RJAALHMKSA-N 0.000 description 1
- MTCJEVAMBYESOT-OALUTQOASA-N C(Cc(cc1)ccc1-c1cnc([C@H]2NCCC2)[nH]1)c1cnc([C@H]2NCCC2)[nH]1 Chemical compound C(Cc(cc1)ccc1-c1cnc([C@H]2NCCC2)[nH]1)c1cnc([C@H]2NCCC2)[nH]1 MTCJEVAMBYESOT-OALUTQOASA-N 0.000 description 1
- VDBISHUWASVPBR-UHFFFAOYSA-N C=[Br]C(C(O)=O)c1ccccc1 Chemical compound C=[Br]C(C(O)=O)c1ccccc1 VDBISHUWASVPBR-UHFFFAOYSA-N 0.000 description 1
- YFBHFJOXDIMCIS-FCMKZANGSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(/C=C/c2ccc(/C=C/c3c[nH]c([C@H]4N(C)CCC4)n3)cc2)[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(/C=C/c2ccc(/C=C/c3c[nH]c([C@H]4N(C)CCC4)n3)cc2)[nH]1)=O YFBHFJOXDIMCIS-FCMKZANGSA-N 0.000 description 1
- IBANDCHWDZXZEF-KRWDZBQOSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(C#Cc2ccc(B(O)O)cc2)[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(C#Cc2ccc(B(O)O)cc2)[nH]1)=O IBANDCHWDZXZEF-KRWDZBQOSA-N 0.000 description 1
- ZXVIAKNQRXHPSH-JTQLQIEISA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(C)[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(C)[nH]1)=O ZXVIAKNQRXHPSH-JTQLQIEISA-N 0.000 description 1
- BUGFPWHHOXZWFP-OBEJDGEISA-N CC(C)C(CNC(OC)=O)C(N(CCC1)[C@@H]1c1ncc(-c2ncc(-c3cnc(-c4cnc([C@H](CCC5)N5C(C(C(C)C)NC(OC)=O)=O)[nH]4)[s]3)[s]2)[nH]1)=O Chemical compound CC(C)C(CNC(OC)=O)C(N(CCC1)[C@@H]1c1ncc(-c2ncc(-c3cnc(-c4cnc([C@H](CCC5)N5C(C(C(C)C)NC(OC)=O)=O)[nH]4)[s]3)[s]2)[nH]1)=O BUGFPWHHOXZWFP-OBEJDGEISA-N 0.000 description 1
- XXJIIQQLIKDFDN-JPMIEVGJSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c2ncc(-c3cnc(-c4cnc([C@H](CCC5)N5C([C@H](C(C)C)NC(OC)=O)=O)[nH]4)[s]3)[s]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c2ncc(-c3cnc(-c4cnc([C@H](CCC5)N5C([C@H](C(C)C)NC(OC)=O)=O)[nH]4)[s]3)[s]2)[nH]1)=O)NC(OC)=O XXJIIQQLIKDFDN-JPMIEVGJSA-N 0.000 description 1
- HKNGCILTDHGUEO-UHFFFAOYSA-N CC1(CO)CCOCC1 Chemical compound CC1(CO)CCOCC1 HKNGCILTDHGUEO-UHFFFAOYSA-N 0.000 description 1
- ORKWOWVNPONBOR-CYBMUJFWSA-N CCN(CC)[C@H](CO)C(OCc1ccccc1)=O Chemical compound CCN(CC)[C@H](CO)C(OCc1ccccc1)=O ORKWOWVNPONBOR-CYBMUJFWSA-N 0.000 description 1
- NCNVFQYIYKPLDB-QHUCILSMSA-N CCOC(C([C@H](C[C@H]12)C[C@@H]1C2(F)F)N=C(c1ccccc1)c1ccccc1)=O Chemical compound CCOC(C([C@H](C[C@H]12)C[C@@H]1C2(F)F)N=C(c1ccccc1)c1ccccc1)=O NCNVFQYIYKPLDB-QHUCILSMSA-N 0.000 description 1
- QXXOMWJCYNPZJG-UHFFFAOYSA-N COC(NC(C1CC(CC2)OC2C1)C(OCc1ccccc1)=O)=O Chemical compound COC(NC(C1CC(CC2)OC2C1)C(OCc1ccccc1)=O)=O QXXOMWJCYNPZJG-UHFFFAOYSA-N 0.000 description 1
- UMTLWTRSWSUNMF-BQBZGAKWSA-N COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)=O Chemical compound COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)=O UMTLWTRSWSUNMF-BQBZGAKWSA-N 0.000 description 1
- UMTLWTRSWSUNMF-RQJHMYQMSA-N COC(N[C@@H]([C@H]1COCCC1)C(O)=O)=O Chemical compound COC(N[C@@H]([C@H]1COCCC1)C(O)=O)=O UMTLWTRSWSUNMF-RQJHMYQMSA-N 0.000 description 1
- DYTJEQBUSOPLJD-NTSWFWBYSA-N CO[C@H](CC1)C[C@H]1O Chemical compound CO[C@H](CC1)C[C@H]1O DYTJEQBUSOPLJD-NTSWFWBYSA-N 0.000 description 1
- PZNMMKDKVFGHBB-UZYDLOFFSA-N C[C@@H]([C@H](C1)N(C)C2)C2N1C(C(O)=O)c1ccccc1 Chemical compound C[C@@H]([C@H](C1)N(C)C2)C2N1C(C(O)=O)c1ccccc1 PZNMMKDKVFGHBB-UZYDLOFFSA-N 0.000 description 1
- RVPFKYFDINHICG-ZDUSSCGKSA-N C[C@@H](c1ccccc1)OC(Cc1ccccc1)=O Chemical compound C[C@@H](c1ccccc1)OC(Cc1ccccc1)=O RVPFKYFDINHICG-ZDUSSCGKSA-N 0.000 description 1
- XVNMENQEXQEQTL-BGKWADHLSA-N C[C@H](C1)O[C@@H](C)CP1C(C(OCc1ccccc1)=O)N=C(c1ccccc1)c1ccccc1 Chemical compound C[C@H](C1)O[C@@H](C)CP1C(C(OCc1ccccc1)=O)N=C(c1ccccc1)c1ccccc1 XVNMENQEXQEQTL-BGKWADHLSA-N 0.000 description 1
- LQWDQTWSVKTRDK-RCEUTCNISA-N C[C@H](C1)O[C@@H](C)C[C@@H]1C(C(O)=O)NC(OC)=O Chemical compound C[C@H](C1)O[C@@H](C)C[C@@H]1C(C(O)=O)NC(OC)=O LQWDQTWSVKTRDK-RCEUTCNISA-N 0.000 description 1
- BHFMWPOZZNNSRV-KVSKUHBBSA-N C[C@H](C1)O[C@@H](C)C[C@@H]1O Chemical compound C[C@H](C1)O[C@@H](C)C[C@@H]1O BHFMWPOZZNNSRV-KVSKUHBBSA-N 0.000 description 1
- SPKSCGXACXWNLJ-ISMYBSGVSA-N C[C@H](C1)O[C@@H](C)C[C@H]1C(C(OCc1ccccc1)=O)NC(OC)=O Chemical compound C[C@H](C1)O[C@@H](C)C[C@H]1C(C(OCc1ccccc1)=O)NC(OC)=O SPKSCGXACXWNLJ-ISMYBSGVSA-N 0.000 description 1
- PRSSGIOADJLTPW-FNEOYCCJSA-N C[C@H]([C@H](CNC(OC)=O)C(N(CCC1)[C@@H]1c1nc(/C=C/c2ccc(/C=C/c3cnc([C@H](CCC4)N4C([C@@H](CNC(OC)=O)[C@@H](C)OC)=O)[nH]3)cc2)c[nH]1)=O)NC Chemical compound C[C@H]([C@H](CNC(OC)=O)C(N(CCC1)[C@@H]1c1nc(/C=C/c2ccc(/C=C/c3cnc([C@H](CCC4)N4C([C@@H](CNC(OC)=O)[C@@H](C)OC)=O)[nH]3)cc2)c[nH]1)=O)NC PRSSGIOADJLTPW-FNEOYCCJSA-N 0.000 description 1
- JHXKGCLHEYMKHG-UHFFFAOYSA-N NC(C1CC(CC2)OC2C1)C(OCc1ccccc1)=O Chemical compound NC(C1CC(CC2)OC2C1)C(OCc1ccccc1)=O JHXKGCLHEYMKHG-UHFFFAOYSA-N 0.000 description 1
- YLCUFCOHXOJILF-UHFFFAOYSA-N O=C(CBr)c1cnc(-c2ncc(C(CBr)=O)[s]2)[s]1 Chemical compound O=C(CBr)c1cnc(-c2ncc(C(CBr)=O)[s]2)[s]1 YLCUFCOHXOJILF-UHFFFAOYSA-N 0.000 description 1
- XPRRFTHGWKHATR-GFCCVEGCSA-N OC([C@@H](c1ccccc1)N1CCCCC1)=O Chemical compound OC([C@@H](c1ccccc1)N1CCCCC1)=O XPRRFTHGWKHATR-GFCCVEGCSA-N 0.000 description 1
- GTAFKESWLUCKLS-UHFFFAOYSA-N OC(c(nc1)c(cccc2)c2c1N1CCOCC1)=O Chemical compound OC(c(nc1)c(cccc2)c2c1N1CCOCC1)=O GTAFKESWLUCKLS-UHFFFAOYSA-N 0.000 description 1
- SMSLWFZHCONMGQ-UHFFFAOYSA-N c1c[s]c(-c2ncc[s]2)n1 Chemical compound c1c[s]c(-c2ncc[s]2)n1 SMSLWFZHCONMGQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26056909P | 2009-11-12 | 2009-11-12 | |
| US61/260569 | 2009-11-12 | ||
| US12/942,183 US20110281910A1 (en) | 2009-11-12 | 2010-11-09 | Hepatitis C Virus Inhibitors |
| US12/942183 | 2010-11-09 | ||
| PCT/US2010/056114 WO2011060000A1 (en) | 2009-11-12 | 2010-11-10 | Hepatitis c virus inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102712628A CN102712628A (zh) | 2012-10-03 |
| CN102712628B true CN102712628B (zh) | 2014-10-15 |
Family
ID=43334735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080061374.4A Expired - Fee Related CN102712628B (zh) | 2009-11-12 | 2010-11-10 | 丙型肝炎病毒抑制剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20110281910A1 (enExample) |
| EP (1) | EP2499132B1 (enExample) |
| JP (1) | JP5697679B2 (enExample) |
| CN (1) | CN102712628B (enExample) |
| WO (1) | WO2011060000A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075376A2 (en) * | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| WO2010075380A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2419404B1 (en) * | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
| RS56654B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| RU2452735C1 (ru) * | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| IN2014MN01547A (enExample) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| NZ729172A (en) | 2013-01-31 | 2018-06-29 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN111116563B (zh) * | 2013-06-06 | 2023-07-04 | 上海爱博医药科技有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN105985356B (zh) * | 2015-02-05 | 2018-06-22 | 四川大学 | 咪唑[2,1-b]噻唑衍生物及其制备方法和用途 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| GB2552919A (en) * | 2015-11-18 | 2018-02-21 | Azad Pharmaceutical Ingredients Ag | Stable amorphous form of daclatasvir |
| JP7725617B2 (ja) | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
| CA3219397A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558059A (zh) * | 2006-08-11 | 2009-10-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2153987A1 (en) | 1993-01-14 | 1994-07-21 | U. Prasad Kari | Amino acids and peptides having modified terminals |
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP1532118A2 (en) | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| EP2038253A1 (en) | 2006-05-30 | 2009-03-25 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| JP2010504281A (ja) | 2006-07-27 | 2010-02-12 | エミスフェアー・テクノロジーズ・インク | アリールスルファニル化合物、および活性薬剤を送達するための組成物 |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100055071A1 (en) | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| KR20100123717A (ko) | 2008-02-12 | 2010-11-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 |
| HRP20120440T1 (hr) | 2008-02-12 | 2012-06-30 | Bristol-Myers Squibb Company | Inhibitori virusa hepatitisa c |
| PL2242752T3 (pl) | 2008-02-13 | 2012-12-31 | Bristol Myers Squibb Co | Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
| WO2010075376A2 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| ES2606717T3 (es) | 2009-02-27 | 2017-03-27 | Enanta Pharmaceuticals, Inc. | Inhibidores del virus de la hepatitis C |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| CN102427729B (zh) | 2009-03-27 | 2014-09-03 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2419404B1 (en) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Anti-viral compounds |
| CA2759142A1 (en) | 2009-04-24 | 2010-10-28 | Tibotec Pharmaceuticals | Diaryl ethers |
| US9139569B2 (en) | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| RS56654B8 (sr) * | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8772505B2 (en) | 2009-05-29 | 2014-07-08 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| CA2768637A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| EP2462135A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| RU2012112824A (ru) | 2009-09-03 | 2013-10-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| AU2010324871A1 (en) | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| TWI429645B (en) | 2009-12-04 | 2014-03-11 | Proline derivatives | |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| US20130072523A1 (en) | 2009-12-24 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| CN102843909A (zh) | 2010-01-25 | 2012-12-26 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| JP2013518062A (ja) | 2010-01-28 | 2013-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
-
2010
- 2010-11-09 US US12/942,183 patent/US20110281910A1/en not_active Abandoned
- 2010-11-10 EP EP10779401.8A patent/EP2499132B1/en not_active Not-in-force
- 2010-11-10 JP JP2012538923A patent/JP5697679B2/ja not_active Expired - Fee Related
- 2010-11-10 CN CN201080061374.4A patent/CN102712628B/zh not_active Expired - Fee Related
- 2010-11-10 WO PCT/US2010/056114 patent/WO2011060000A1/en not_active Ceased
-
2012
- 2012-09-12 US US13/611,708 patent/US8618153B2/en active Active
-
2013
- 2013-09-16 US US14/027,531 patent/US20140018389A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558059A (zh) * | 2006-08-11 | 2009-10-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011060000A1 (en) | 2011-05-19 |
| US20140018389A1 (en) | 2014-01-16 |
| CN102712628A (zh) | 2012-10-03 |
| JP2013510857A (ja) | 2013-03-28 |
| US20110281910A1 (en) | 2011-11-17 |
| US20130012540A1 (en) | 2013-01-10 |
| JP5697679B2 (ja) | 2015-04-08 |
| EP2499132B1 (en) | 2017-02-15 |
| EP2499132A1 (en) | 2012-09-19 |
| US8618153B2 (en) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102712628A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459250B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102712623B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102791693B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459281B (zh) | 丙型肝炎病毒抑制剂 | |
| TWI547480B (zh) | Ｃ型肝炎病毒抑制劑 | |
| CN102177141B (zh) | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 | |
| CN102395579B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102448956B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102378762B (zh) | 丙型肝炎病毒抑制剂 | |
| CN103153986B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN101998954B (zh) | 用作丙型肝炎病毒抑制剂的构象受限的联苯衍生物 | |
| TWI487702B (zh) | Ｃ型肝炎病毒抑制劑 | |
| CN102143959B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102803249A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459239A (zh) | 丙型肝炎病毒抑制剂 | |
| CN101754966A (zh) | 丙型肝炎病毒抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141015 Termination date: 20161110 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |